CN1778323B - A drug drop pill for treating cardiovascular disease - Google Patents
A drug drop pill for treating cardiovascular disease Download PDFInfo
- Publication number
- CN1778323B CN1778323B CN 200410072940 CN200410072940A CN1778323B CN 1778323 B CN1778323 B CN 1778323B CN 200410072940 CN200410072940 CN 200410072940 CN 200410072940 A CN200410072940 A CN 200410072940A CN 1778323 B CN1778323 B CN 1778323B
- Authority
- CN
- China
- Prior art keywords
- film
- ultrafiltration
- membrane
- chinese medicine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000006187 pill Substances 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 title description 3
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 92
- 239000000284 extract Substances 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 25
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 22
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 22
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 22
- 238000005352 clarification Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 57
- 239000012528 membrane Substances 0.000 claims description 50
- 230000000737 periodic effect Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 12
- 229920002492 poly(sulfone) Polymers 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 229920006393 polyether sulfone Polymers 0.000 claims description 10
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 9
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 8
- 239000004695 Polyether sulfone Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 239000002033 PVDF binder Substances 0.000 claims description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 235000002791 Panax Nutrition 0.000 claims 3
- 241000208343 Panax Species 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 229910052756 noble gas Inorganic materials 0.000 claims 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- 235000015073 liquid stocks Nutrition 0.000 claims 1
- 238000011017 operating method Methods 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 21
- 229940116229 borneol Drugs 0.000 abstract description 21
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 21
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 21
- 239000002994 raw material Substances 0.000 abstract description 9
- 208000029078 coronary artery disease Diseases 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000000126 substance Substances 0.000 description 23
- 238000004140 cleaning Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000011001 backwashing Methods 0.000 description 10
- 239000012459 cleaning agent Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940057995 liquid paraffin Drugs 0.000 description 8
- 108090000862 Ion Channels Proteins 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 7
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 6
- 238000009295 crossflow filtration Methods 0.000 description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 4
- 239000008678 sanqi Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000007718 Stable Angina Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920002284 Cellulose triacetate Polymers 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000244365 Ligusticum sinense Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- -1 dilute alkalis Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000009277 Panax notoginseng extract Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种中药滴丸,它以川芎、三七和冰片为原料药,其制备工艺步骤为:(1)将川芎和三七混合或单独制成水提液或醇提液;(2)对所述的提取液进行初步澄清处理;(3)进一步对所述的提取液进行超滤处理;(4)将超滤液浓缩,加入冰片,制成滴丸。本发明药物对冠心病心绞痛具有良好的治疗作用。The invention discloses a traditional Chinese medicine dripping pill, which uses chuanxiong, notoginseng and borneol as raw materials, and the preparation process steps are: (1) mixing the chuanxiong and notoginseng to prepare a water extract or an alcohol extract; ( 2) performing preliminary clarification treatment on the extract; (3) further performing ultrafiltration on the extract; (4) concentrating the ultrafiltrate, adding borneol, and making drop pills. The medicine of the invention has good therapeutic effect on coronary heart disease angina pectoris.
Description
技术领域technical field
本发明涉及一种治疗心血管疾病的药物滴丸,属于中药领域。The invention relates to a medicinal dripping pill for treating cardiovascular diseases, which belongs to the field of traditional Chinese medicines.
背景技术Background technique
随着生活水平的提高、世界人口老龄化及发病群体的年轻化,心脑血管病人逐年增加,已经成为危害人类健康的第二大疾病。心绞痛是一种由心肌暂时缺血、缺氧所引起的,以发作性胸痛或胸部不适为主要表现的临床综合症。冠心病心绞痛是指由于冠状动脉硬化或痉挛导致心肌缺血、缺氧所引起的心绞痛,约占心绞痛患者的90%。With the improvement of living standards, the aging of the world's population and the rejuvenation of the disease population, cardiovascular and cerebrovascular patients are increasing year by year, and have become the second largest disease that endangers human health. Angina pectoris is a clinical syndrome caused by temporary myocardial ischemia and hypoxia, with episodic chest pain or chest discomfort as the main manifestation. Coronary heart disease angina pectoris refers to angina pectoris caused by myocardial ischemia and hypoxia due to coronary artery sclerosis or spasm, accounting for about 90% of angina pectoris patients.
目前治疗心绞痛的方法以扩张血管、降低血黏度、抗血小板聚集、抗凝血为主。应用的传统西药为硝酸酯、亚硝酸酯类、β-受体阻制剂、钙拮抗剂等,但是均存在较大的毒副作用,不宜长期服用,多为症状性的治疗而对病程进展无较大作用。例如服用硝酸甘油后有时会出现头胀、头内跳痛、心跳加快,甚至昏厥[参见新编药物学[第14版)264页],近年来又发现有致严重低血压[参见中国现代医学杂志1997;7(4):42;陕西医学杂志1996;25(5):315]、易产生耐受性[参见南方护理杂志1996;3(5):7~9]等问题,阻碍了其在临床上的应用。The current methods of treating angina pectoris mainly focus on dilating blood vessels, reducing blood viscosity, anti-platelet aggregation, and anti-coagulation. The traditional western medicines used are nitrates, nitrites, β-receptor blockers, calcium antagonists, etc., but all of them have relatively large toxic and side effects, and should not be taken for a long time. great effect. For example, after taking nitroglycerin, sometimes there will be dizziness, throbbing pain in the head, rapid heartbeat, and even fainting [see the new pharmacology [14th edition] page 264], and it has been found to cause severe hypotension in recent years [see Chinese Journal of Modern Medicine 1997; 7(4): 42; Shaanxi Medical Journal 1996; 25(5): 315], prone to tolerance [see Southern Nursing Journal 1996; 3(5): 7~9] and other issues, which hinder its use in clinical application.
虽然亦有不少治疗心绞痛的中成药,其中丸、散、膏、丹、汤剂早已成为古老的历史,现代人极少应用。目前市场上有普通复方丹参片剂和胶囊等制剂出售,但普通片剂、胶囊生产工艺较落后,有效成分含量低,无质量控制标准,需口服经胃肠道吸收,在肝脏发生首过效应后吸收入血,生物利用度低,吸收慢,并不能适合心绞痛病人的急救之需。Although there are many Chinese patent medicines for treating angina pectoris, pills, powders, creams, pills, and decoctions have long been ancient and are rarely used by modern people. At present, there are ordinary compound Danshen tablets and capsules on the market, but the production process of ordinary tablets and capsules is relatively backward, the content of active ingredients is low, and there is no quality control standard. They need to be taken orally and absorbed through the gastrointestinal tract, and the first-pass effect occurs in the liver. After being absorbed into the blood, the bioavailability is low and the absorption is slow, so it is not suitable for the first aid needs of patients with angina pectoris.
复方川芎滴丸是一种起效快、疗效好的冠心病治疗药物,临床上深受患者的欢迎。本发明人从提取工艺方面进行了深入研究,完成了本发明。Compound Chuanxiong Dropping Pills is a drug for the treatment of coronary heart disease with fast onset and good curative effect, and is very popular among patients in clinic. The present inventor has carried out in-depth research from the extraction technology aspect, has completed the present invention.
发明内容Contents of the invention
本发明的目的在于提供一种治疗心血管疾病的中药滴丸。The object of the present invention is to provide a kind of traditional Chinese medicine dripping pill for treating cardiovascular disease.
本发明通过以下方案予以实施:The present invention is implemented through the following schemes:
本发明药物是通过下述技术步骤实现的:以川芎、三七和冰片为原料药,按照以下步骤进行制备:The medicine of the present invention is realized through the following technical steps: taking Rhizoma Chuanxiong, Radix Notoginseng and Borneolum as raw materials, prepare according to the following steps:
(1)将川芎、三七混合或单独制成水提液或醇提液;(1) Mix Rhizoma Chuanxiong and Panax notoginseng or make water extract or alcohol extract separately;
(2)对所述的提取液进行初步澄清处理;(2) Carry out preliminary clarification treatment to described extract;
(3)进一步对所述的提取液进行超滤处理;(3) further carry out ultrafiltration treatment to described extract;
(4)将超滤液浓缩成浸膏;将所得浸膏与冰片及辅料混和均匀后,制成滴丸制剂。(4) Concentrate the ultrafiltrate into an extract; mix the obtained extract with borneol and auxiliary materials evenly, and make a drop pill preparation.
上述原料药的重量百分比为:川芎20%~97%,三七2%~79%,冰片0.2%~3%;优选为川芎63.0%%~94%,三七4.0%~35.0%,冰片0.5%~2.0%;更优选为川芎75.2%~90%,三七9%~23.5%,冰片0.5%~1.3%。川芎、三七、冰片的重量百分比之和为100%。The weight percentages of the above-mentioned raw materials are: Rhizoma Chuanxiong 20%~97%, Radix Notoginseng 2%~79%, Borneol 0.2%~3%; Preferably Chuanxiong 63.0%%~94%, Radix Notoginseng 4.0%~35.0%, Borneol 0.5% %~2.0%; more preferably Chuanxiong 75.2%~90%, Panax notoginseng 9%~23.5%, Borneol 0.5%~1.3%. The sum of the percentages by weight of Rhizoma Chuanxiong, Panax notoginseng and Borneol is 100%.
本发明技术步骤(1)中,醇提液可为不同浓度的低级醇如甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇等的提取液或其混合物的提取液.醇提液可不浓缩或适当浓缩后进行下一步的初步澄清处理.In the technical step (1) of the present invention, the alcohol extract can be an extract of different concentrations of lower alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol or a mixture thereof. The alcohol extract can be subjected to the next step of preliminary clarification after being not concentrated or properly concentrated.
本发明技术步骤(2)中,初步的澄清处理可用一般的材料如纱布、丝绢等进行粗滤,也可用较专业的材料如陶瓷膜进行微滤,也可经高速离心后分取上清液,也可用絮凝剂如壳聚糖絮凝澄清剂、101果汁澄清剂、ZTC1+1天然澄清剂、蛋清絮凝剂等吸附澄清而除去药液中较大的悬浮颗粒,还可用醇沉法除去大部份杂质。既可单用上述澄清方法,也可联合应用,例如粗滤-吸附澄清,吸附澄清-高速离心,粗滤-微滤,粗滤-醇沉等。初步澄清处理的溶液可不浓缩或适当浓缩后进行下一步的超滤;优选不进行浓缩即进行下一步的超滤。In the technical step (2) of the present invention, preliminary clarification treatment can carry out rough filtration with general material such as gauze, silk silk etc., also can carry out microfiltration with more professional material such as ceramic membrane, also can get supernatant after high-speed centrifugation Liquid, also can use flocculant such as chitosan flocculation clarifier, 101 fruit juice clarifier, ZTC1+1 natural clarifier, egg white flocculant etc. Some impurities. The above clarification methods can be used alone or in combination, such as coarse filtration-adsorption clarification, adsorption clarification-high-speed centrifugation, coarse filtration-microfiltration, coarse filtration-alcohol precipitation, etc. The solution that has been preliminarily clarified can be subjected to the next step of ultrafiltration without concentration or after being properly concentrated; preferably, the next step of ultrafiltration is performed without concentration.
本发明技术步骤(3)中,超滤所用的超滤膜可为二醋酸纤维素膜(CA)、三醋酸纤维素膜(CTA)、氰乙基醋酸纤维素膜(CN-CA)、聚砜膜(PS)、磺化聚砜膜(SPS)、聚醚砜膜(PES)、磺化聚醚砜膜(SPES)、聚砜酰胺膜(PSA)、酚酞侧基聚芳砜膜(PDS)、聚偏氟乙烯膜(PVDF)、聚丙烯腈膜(PAN)、聚酰亚胺膜(N)、纤维素膜、甲基丙烯酸甲酯-丙烯腈共聚物膜(MMA-AN)、聚丙烯腈/二醋酸纤维素(PAN/CA)共混膜,动态形成的超滤膜,以及上述膜的改性膜。优选为二醋酸纤维素膜(CA)、三醋酸纤维素膜(CTA)、聚砜膜(PS)、磺化聚砜膜(SPS)、聚醚砜膜(PES)、磺化聚醚砜膜(SPES)、聚砜酰胺膜(PSA),聚偏氟乙烯膜(PVDF)、聚丙烯腈膜(PAN)。In the technical step (3) of the present invention, the ultrafiltration membrane used for ultrafiltration can be cellulose diacetate membrane (CA), cellulose triacetate membrane (CTA), cyanoethyl cellulose acetate membrane (CN-CA), polyester Sulfone membrane (PS), sulfonated polysulfone membrane (SPS), polyethersulfone membrane (PES), sulfonated polyethersulfone membrane (SPES), polysulfone amide membrane (PSA), phenolphthalein side group polyarylsulfone membrane (PDS) ), polyvinylidene fluoride film (PVDF), polyacrylonitrile film (PAN), polyimide film (N), cellulose film, methyl methacrylate-acrylonitrile copolymer film (MMA-AN), poly Acrylonitrile/cellulose diacetate (PAN/CA) blend membranes, dynamically formed ultrafiltration membranes, and modified membranes of the above membranes. Preferably cellulose diacetate membrane (CA), cellulose triacetate membrane (CTA), polysulfone membrane (PS), sulfonated polysulfone membrane (SPS), polyethersulfone membrane (PES), sulfonated polyethersulfone membrane (SPES), polysulfoneamide membrane (PSA), polyvinylidene fluoride membrane (PVDF), polyacrylonitrile membrane (PAN).
上述超滤膜的截留分子量一般为6000~80000,优选为10000~70000,最佳为20000~50000。The molecular weight cut-off of the ultrafiltration membrane is generally 6000-80000, preferably 10000-70000, most preferably 20000-50000.
超滤既可采用错流过滤,也可采用死端过滤,但优选错流过滤。Ultrafiltration can be either cross-flow filtration or dead-end filtration, but cross-flow filtration is preferred.
超滤工艺的操作条件如下:The operating conditions of the ultrafiltration process are as follows:
(1)超滤的进液口压力为0.1~0.5MPa,优选为0.1~0.35Mpa,最佳为0.25~0.35Mpa;超滤的出液口压力比进液口压力低0.5~0.25kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.1~0.2Mpa。(1) The inlet pressure of the ultrafiltration is 0.1-0.5MPa, preferably 0.1-0.35Mpa, and most preferably 0.25-0.35Mpa; the outlet pressure of the ultrafiltration is 0.5-0.25kPa lower than the inlet pressure. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.1-0.2Mpa.
(2)料液流速为1.0~4.0m/s,优选为2.0~3.0m/s。超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为1.0~2.0m/s。(2) The flow rate of the feed liquid is 1.0-4.0 m/s, preferably 2.0-3.0 m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unsteady flow in the membrane channel, and the flow velocity fluctuation difference is 1.0-2.0m/s.
(3)在超滤系统中间歇通入高压惰性气体如氮气,形成气液脉冲流,周期为0.5h~2h通气一次,每次1分钟。(3) In the ultrafiltration system, high-pressure inert gas such as nitrogen is fed intermittently to form a gas-liquid pulse flow, and the cycle is 0.5h-2h to ventilate once, each time for 1 minute.
(3)料液温度为15~50℃,优选为20~40℃。(3) The feed liquid temperature is 15-50°C, preferably 20-40°C.
(4)当料液原液被浓缩1/15~1/5时,再加水或稀醇溶液超滤1~2次;优选为当料液原液被浓缩1/12~1/8时,再加水或稀醇溶液超滤1~2次。(4) When the stock solution is concentrated by 1/15 to 1/5, add water or dilute alcohol solution for ultrafiltration 1 to 2 times; preferably when the stock solution is concentrated by 1/12 to 1/8, add water Or dilute alcohol solution ultrafiltration 1 to 2 times.
(5)料液的PH值控制在5~9,优选为6.0~7.5;(5) The pH value of the feed liquid is controlled at 5 to 9, preferably 6.0 to 7.5;
(6)反冲洗条件:反冲洗压力为0.15~2.5MPa,反冲洗周期为0.5~1.5h、反冲洗时间为1min~10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,一般是工作10~20min,反冲30sec~3min。(6) Backwashing conditions: Backwashing pressure is 0.15-2.5MPa, backwashing cycle is 0.5-1.5h, and backwashing time is 1min-10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time To carry out, generally work for 10 to 20 minutes, and recoil for 30 seconds to 3 minutes.
(7)化学清洗周期为0.5个月~2个月,化学清洗药剂一般为稀酸、稀碱、表面活性剂,优选为稀碱例如0.5%~4.0%氢氧化钠,1.5%氢氧化钠和2%次氯酸钠的混合溶液等,pH值为10~12,清洗工作压力为0.05~1.0MPa.在用化学清洗剂清洗之后,再用水冲洗至近中性.(7) The chemical cleaning cycle is 0.5 months to 2 months. The chemical cleaning agents are generally dilute acids, dilute alkalis, and surfactants, preferably dilute alkalis such as 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and The mixed solution of 2% sodium hypochlorite, etc., the pH value is 10-12, and the cleaning working pressure is 0.05-1.0MPa. After cleaning with chemical cleaning agent, rinse with water until it is nearly neutral.
在超滤过程中,既可单独使用周期性压力波动或者周期性流量波动或者周期性通入惰性气体,也可联合使用,即周期性压力波动和周期性流量波动联合使用,或者周期性压力波动和周期性通入惰性气体联合使用,或者周期性流量波动和周期性通入惰性气体联合使用,或者三者一起联合使用。In the ultrafiltration process, periodic pressure fluctuations or periodic flow fluctuations or periodic inert gas injections can be used alone, or in combination, that is, periodic pressure fluctuations and periodic flow fluctuations are used in combination, or periodic pressure fluctuations It is used in combination with periodic inert gas injection, or in combination with periodic flow fluctuations and inert gas injection, or in combination with the three.
本发明技术步骤(4)中,将超滤液浓缩成浸膏后,与冰片及辅料混和均匀后,加热化料,移入滴丸机的滴罐,药液滴至低温液体石蜡中,除去液体石蜡,选丸。In the technical step (4) of the present invention, after the ultrafiltrate is concentrated into an extractum, after mixing evenly with borneol and auxiliary materials, the chemical material is heated, moved into the dropping tank of the dropping pill machine, and the medicinal liquid is dropped into low-temperature liquid paraffin to remove the liquid Paraffin, choose pills.
其中:辅料为聚乙二醇-6000,其凝点53~58℃,加入量为浸膏与冰片重量的2~6倍;化料温度为60~100℃;液体石蜡的温度为0~10℃(最佳为5~10℃);丸重为5~50mg/粒,直径1.95~4.29mm。Among them: the auxiliary material is polyethylene glycol-6000, its freezing point is 53-58 °C, and the addition amount is 2-6 times the weight of the extract and borneol; the temperature of the chemical material is 60-100 °C; the temperature of the liquid paraffin is 0-10 °C. ℃ (optimally 5-10 ℃); pellet weight 5-50mg/granule, diameter 1.95-4.29mm.
本发明药物治疗冠心病心绞痛疗效突出。The medicine of the invention has outstanding curative effect in treating angina pectoris of coronary heart disease.
实验例本发明中药滴丸治疗冠心病心绞痛临床疗效观察Experimental example Chinese medicine dripping pill of the present invention treats clinical curative effect observation of coronary heart disease angina pectoris
一般资料normal information
1、病例选择:选择我院门诊和住院的冠心病心绞痛患者52例,其中住院患者38例,门诊患者14例均符合WHO冠心病心绞痛诊断标准:其中稳定型心绞痛(SA)36例,不稳定型心绞痛(VA)14例,伴有心律失常20例;男性36例,女性16例,年龄40岁~68岁(54.52±10.08岁)。1. Case selection: 52 outpatients and inpatients with coronary heart disease and angina pectoris in our hospital were selected, including 38 inpatients and 14 outpatients who met the WHO diagnostic criteria for coronary heart disease and angina pectoris: 36 cases of stable angina (SA), unstable Type angina pectoris (VA) in 14 cases, accompanied by arrhythmia in 20 cases; male 36 cases, female 16 cases, aged 40 to 68 years old (54.52 ± 10.08 years).
2、方法:本发明中药滴丸,每日口服3次,每次10粒,疗程2个月。观察治疗前后观察心绞痛发作情况、心电图变化、血液流变学改变等。血浆粘度(PV),全血粘度(WBV)检查采用国际公认的锥板血液粘度计,(成都仪器厂制造NXE-I型)红细胞压积(Hct)和纤维蛋白(Fib),用微量毛细血管方法,CR-III型压积仪同时完成,PAG MAX为MG型血小板聚集仪的最大聚集率。2, method: Chinese medicine dripping pill of the present invention, every day is taken orally 3 times, each 10, and the course of treatment is 2 months. The onset of angina pectoris, changes in electrocardiogram, and changes in hemorrheology were observed before and after treatment. Plasma viscosity (PV) and whole blood viscosity (WBV) were checked using an internationally recognized cone-plate blood viscometer, (manufactured by Chengdu Instrument Factory NXE-I type) hematocrit (Hct) and fibrin (Fib), with microcapillary Methods, the CR-III platelet aggregation instrument was completed at the same time, and PAG MAX was the maximum aggregation rate of the MG platelet aggregation instrument.
疗效判断标准Efficacy Judgment Criteria
1、心绞痛症状:心绞痛完全消失或减少发作次数超过治疗前90%以上者为显效;减少次数超过治疗前50%以上,但未达到90%者为有效;心绞痛症状无减少或减少次数不足治疗前总数的50%为无效。1. Symptoms of angina pectoris: It is markedly effective if the angina pectoris completely disappears or the number of attacks is reduced by more than 90% before treatment; it is effective if the number of attacks is reduced by more than 50% but less than 90% before treatment; there is no reduction in symptoms of angina pectoris or the number of attacks is less than before treatment 50% of the total is invalid.
2、心电图:治疗前后观察心电图ST-T改变,治疗后ST-T恢复正常或有明显下降恢复到接近正常,负荷心电图试验由阳性转为阴性者为有效,治疗后无改变,负荷心电图试验仍为阳性者为无效。2. Electrocardiogram: Observe the ST-T changes of ECG before and after treatment. After treatment, ST-T returns to normal or has a significant decline and returns to near normal. It is effective if the stress ECG test turns from positive to negative. There is no change after treatment, and the stress ECG test remains unchanged. Those who are positive are invalid.
3、心律失常:治疗后心律失常消失或减少≥50%为有效。3. Arrhythmia: It is effective if the arrhythmia disappears or decreases by ≥50% after treatment.
统计学方法Statistical method
各种数据均值以(x±s)表示,均值比较用t检验,率的比较用X2检验。The means of various data are represented by (x±s), and the comparison of means is by t test, and the comparison of rates is by X 2 test.
结果result
1、心绞痛症状 临床疗效观察本发明中药滴丸对稳定型心绞痛效果优于不稳定型心绞痛,有效率分别为90.48%和74.1%组间比较P<0.01。见表1。1. Symptoms of angina pectoris Clinical curative effect observation The traditional Chinese medicine dripping pill of the present invention is better than unstable angina pectoris to stable angina pectoris, and the effective rate is respectively 90.48% and 74.1%. P<0.01 among groups. See Table 1.
表1心绞痛的疗效观察Table 1 Curative effect observation of angina pectoris
2、心电图改善情况治疗前心电图ST-T异常者41例,治疗后有效者为22例,有效率为53.6%。2. Improvement of electrocardiogram There were 41 cases with abnormal ST-T of electrocardiogram before treatment, and 22 cases were effective after treatment, the effective rate was 53.6%.
3、心律失常改善情况伴有心律失常20例,治疗后有效10例,有效率50%。3. Arrhythmia improved in 20 cases accompanied by arrhythmia, 10 cases were effective after treatment, and the effective rate was 50%.
4、血液流变学变化情况治疗前后测定血小板聚集率、全血粘度高切值、血浆粘度、红细胞压积、纤维蛋白原等指标结果表明复方川芎滴丸对血小板聚集率和血液粘度有明显的改善作用。见表2。4. Changes in blood rheology The results of measuring platelet aggregation rate, whole blood viscosity high cut value, plasma viscosity, hematocrit, fibrinogen and other indicators before and after treatment showed that compound Chuanxiong dripping pills had a significant effect on platelet aggregation rate and blood viscosity. Improvement effect. See Table 2.
表2本发明中药滴丸对冠心病心绞痛患者血流变学影响Table 2 Chinese medicine dripping pills of the present invention have influence on hemorrheology of patients with coronary heart disease angina pectoris
具体实施方式Detailed ways
以下结合实施例对本发明作进一步的阐述。这些实施例仅用于例举的目的,而不是以任何方式限制本发明。The present invention will be further elaborated below in conjunction with embodiment. These examples are for illustrative purposes only and do not limit the invention in any way.
实施例一Embodiment one
原料药采用川芎55.8g、三七3.4g、冰片0.8g。The raw materials are 55.8g of Rhizoma Chuanxiong, 3.4g of Radix Notoginseng, and 0.8g of Borneol.
用乙醇提取川芎和三七,得到川芎和三七的乙醇提取液,用纱布将此提取液过滤,收集滤液。滤液用截留分子量为6000的二醋酸纤维素膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.1Mpa,超滤的出液口压力比进液口压力低0.5kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.1Mpa。料液流速为1.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为1.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为0.5h通气一次,每次1分钟。料液温度为15℃,当料液原液被浓缩1/15时,再加水或稀醇溶液超滤1次,料液的PH值控制在5。反冲洗压力为0.15MPa,反冲洗周期为0.5h、反冲洗时间为1min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作10min,反冲30sec。化学清洗周期为0.5月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为0.05MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Extract Chuanxiong and Sanqi with ethanol to obtain the ethanol extract of Chuanxiong and Sanqi, filter the extract with gauze, and collect the filtrate. The filtrate was ultrafiltered with a cellulose diacetate membrane with a molecular weight cut-off of 6000, and the filtration method was cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.1Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.5kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are used, and the pressure fluctuation difference is 0.1Mpa. The flow rate of the feed liquid is 1.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 1.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 0.5h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 15°C. When the original feed liquid is concentrated by 1/15, add water or dilute alcohol solution for ultrafiltration once, and the pH value of the feed liquid is controlled at 5. The backwash pressure is 0.15MPa, the backwash cycle is 0.5h, and the backwash time is 1min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 10min, recoil for 30sec. The chemical cleaning cycle is 0.5 months, the chemical cleaning agent is a mixed solution of 0.5%-4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10-12, and the cleaning working pressure is 0.05MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.
将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-6000 18g混和均匀,加热至温度85℃,化料20~120分钟后,移至罐温保持在85~90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix them evenly with 18g of polyethylene glycol-6000, heat to a temperature of 85°C, and after 20-120 minutes to make the material, move it to a dropping tank of a dripping machine whose tank temperature is kept at 85-90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.
实施例二:Embodiment two:
原料药采用川芎59.3g、三七6.38g、冰片0.34g。The raw materials are Chuanxiong 59.3g, Panax notoginseng 6.38g and Borneol 0.34g.
将粗粉碎的川芎加5倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎1小时,滤过,滤渣弃去,合并滤液,得丹参提取液。用70%乙醇提取三七,得三七提取液。将上述川芎提取液和三七提取液合并,静置,滤过。滤液用截留分子量为80000的聚砜膜进行超滤,过滤方式采用死端过滤。超滤工艺的操作条件为:超滤的进液口压力为0.5Mpa,超滤的出液口压力比进液口压力低0.25kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为4.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为50℃,当料液原液被浓缩1/5时,再加水或稀醇溶液超滤2次,料液的PH值控制在9。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min。化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Add 5 times the amount of water to the coarsely crushed Rhizoma Chuanxiong, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, fry for 1 hour, filter, discard the filter residue, and combine the filtrates to obtain the extract of Salvia miltiorrhiza . Extract the notoginseng with 70% ethanol to obtain the notoginseng extract. The above-mentioned Chuanxiong extract and Panax notoginseng extract were combined, allowed to stand, and filtered. The filtrate was ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 80,000, and the filtration method was dead-end filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.5Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.25kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 4.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 50°C. When the raw liquid of the feed liquid is concentrated by 1/5, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 9. The backwash pressure is 2.5MPa, the backwash cycle is 1.5h, and the backwash time is 10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 20 minutes, recoil for 3 minutes. The chemical cleaning cycle is 2 months, the chemical cleaning agent is a mixed solution of 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10 to 12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.
将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-6000 20g混和均匀,加热至温度85℃,化料20~120分钟后,移至罐温保持在85~90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix them evenly with 20g of polyethylene glycol-6000, heat to a temperature of 85°C, and after 20-120 minutes to make the material, move it to a dropping tank of a dripping machine whose tank temperature is kept at 85-90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.
实施例三:Embodiment three:
原料药采用川芎36.0g、三七23.2g、冰片0.8g。The raw materials are Chuanxiong 36.0g, Panax notoginseng 23.2g and Borneol 0.8g.
用80%乙醇提取川芎和三七,得到川芎和三七的乙醇提取液,将此提取液高速离心后分取上清液。将此液体用截留分子量为50000的聚砜膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.35Mpa,超滤的出液口压力比进液口压力低0.20kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为3.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为40℃,当料液原液被浓缩1/8时,再加水或稀醇溶液超滤2次,料液的PH值控制在7.5。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10mi n.当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min.化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa.在用化学清洗剂清洗之后,再用水冲洗至近中性.The Rhizoma Chuanxiong and Sanqi were extracted with 80% ethanol to obtain the ethanol extract of Rhizoma Chuanxiong and Sanqi, which was centrifuged at high speed and supernatant was collected. The liquid is ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 50,000, and the filtration method adopts cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.35Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.20kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 3.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating or unstable flows in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 40°C. When the original feed liquid is concentrated by 1/8, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 7.5. The backwashing pressure is 2.5MPa, the backwashing cycle is 1.5h, and the backwashing time is 10min. When the ultrafiltration components are connected in parallel to use the method of alternate backflushing, one or several sets of them perform normal ultrafiltration and part of the flow The filtrate is used to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a certain period of time, work for 20 minutes, and backwash for 3 minutes. The chemical cleaning cycle is 2 months, and the chemical cleaning agent is 0.5% to 4.0% sodium hydroxide , a mixed solution of 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10-12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaning agent, rinse with water until nearly neutral.
将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-6000 20g混和均匀,加热至温度60℃,化料20~120分钟后,移至罐温保持在90℃的滴丸机滴罐中。药液滴至7~8℃甲基硅油中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix evenly with 20g of polyethylene glycol-6000, heat to a temperature of 60°C, and after 20 to 120 minutes of compounding, move to a dropping tank of a dripping machine whose tank temperature is kept at 90°C. Drop the drug solution into methyl silicone oil at 7-8°C, take out the dropping pills, remove the oil, select the pills through a screen, and make 1000 dropping pills, to get ready.
实施例四:Embodiment four:
原料药采用川芎41.1g、三七8.0g、冰片0.46g。The raw materials are 41.1g of Chuanxiong, 8.0g of Panax notoginseng, and 0.46g of borneol.
将粗粉碎的川芎、三七药材至提取罐中,加5倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎1小时,滤过,滤渣弃去,合并滤液。滤液用截留分子量为6000的二醋酸纤维素膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.1Mpa,超滤的出液口压力比进液口压力低0.5kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.1Mpa。料液流速为1.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为1.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为0.5h通气一次,每次1分钟。料液温度为15℃,当料液原液被浓缩1/15时,再加水或稀醇溶液超滤1次,料液的PH值控制在5。反冲洗压力为0.15MPa,反冲洗周期为0.5h、反冲洗时间为1min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作10min,反冲30sec。化学清洗周期为0.5月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为0.05MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Put the coarsely crushed Ligusticum chuanxiong and Panax notoginseng into the extraction tank, add 5 times the amount of water, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, fry for 1 hour, filter, and discard the filter residue To, combine the filtrates. The filtrate was ultrafiltered with a cellulose diacetate membrane with a molecular weight cut-off of 6000, and the filtration method was cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.1Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.5kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are used, and the pressure fluctuation difference is 0.1Mpa. The flow rate of the feed liquid is 1.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 1.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 0.5h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 15°C. When the original feed liquid is concentrated by 1/15, add water or dilute alcohol solution for ultrafiltration once, and the pH value of the feed liquid is controlled at 5. The backwash pressure is 0.15MPa, the backwash cycle is 0.5h, and the backwash time is 1min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 10min, recoil for 30sec. The chemical cleaning cycle is 0.5 months, the chemical cleaning agent is a mixed solution of 0.5%-4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10-12, and the cleaning working pressure is 0.05MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.
将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-6000 21g混和均匀,加热至温度60℃,化料20~120分钟后,移至罐温保持在90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix evenly with 21g of polyethylene glycol-6000, heat to a temperature of 60°C, and after 20 to 120 minutes of compounding, move to a dropping tank of a dropping pill machine whose tank temperature is kept at 90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.
实施例五:Embodiment five:
原料药采用川芎29.0g、三七30.6g、冰片0.6g。The raw materials are Chuanxiong 29.0g, Panax notoginseng 30.6g and Borneol 0.6g.
将粗粉碎的川芎、三七药材至提取罐中,加5倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎1小时,滤过,滤渣弃去,合并滤液.滤液用截留分子量为80000的聚砜膜进行超滤,过滤方式采用死端过滤.超滤工艺的操作条件为:超滤的进液口压力为0.5Mpa,超滤的出液口压力比进液口压力低0.25kPa.超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa.料液流速为4.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟.料液温度为50℃,当料液原液被浓缩1/5时,再加水或稀醇溶液超滤2次,料液的PH值控制在9.反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min.当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min.化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa.在用化学清洗剂清洗之后,再用水冲洗至近中性.Put the coarsely crushed Ligusticum chuanxiong and Panax notoginseng into the extraction tank, add 5 times the amount of water, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, fry for 1 hour, filter, and discard the filter residue Go and combine the filtrates. The filtrate is ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 80,000, and the filtration method adopts dead-end filtration. The operating conditions of the ultrafiltration process are: the pressure of the ultrafiltration inlet is 0.5Mpa, and the ultrafiltration outlet is 0.5Mpa. The inlet pressure is 0.25kPa lower than the liquid inlet pressure. The initial ultrafiltration adopts a lower pressure, and then slowly increases the pressure; in the ultrafiltration process, adopts periodic pressure fluctuations, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 4.0m /s, during the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel, and the flow velocity fluctuation difference is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system to form a gas-liquid pulse flow The period is 2 hours to ventilate once, each time for 1 minute. The temperature of the feed liquid is 50°C. When the raw liquid of the feed liquid is concentrated by 1/5, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 9. The backwashing pressure is 2.5MPa, the backwashing period is 1.5h, and the backwashing time is 10min. When the ultrafiltration components are connected in parallel to use alternate backflushing, one or several sets of them perform normal ultrafiltration and part of the filtrate To recoil the ultrafiltration membrane of another set or several sets of components, exchange after a period of time, work for 20 minutes, and recoil for 3 minutes. The chemical cleaning cycle is 2 months, and the chemical cleaning agent is 0.5% to 4.0% sodium hydroxide, The mixed solution of 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10-12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaning agent, rinse with water until nearly neutral.
将所述的超滤液浓缩得到相对密度为1.32~1.40(55℃)的浸膏,取浸膏和冰片,与聚乙二醇-600020g混和均匀,加热至温度60℃,化料20~120分钟后,移至罐温保持在90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrate the ultrafiltrate to obtain an extract with a relative density of 1.32 to 1.40 (55°C), take the extract and borneol, mix it with polyethylene glycol-600020g, heat to a temperature of 60°C, and mix 20 to 120 After 10 minutes, move to the dripping tank of the dropping pill machine where the tank temperature is kept at 90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.
实施例六:Embodiment six:
原料药采用川芎21.0g、三七38.0g、冰片0.4g。The raw materials are Chuanxiong 21.0g, Panax notoginseng 38.0g, and Borneol 0.4g.
取经粗粉碎的川芎、三七药材至提取罐中,加入0.89g碳酸氢钠,加4倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎煮1小时,滤过,滤渣弃去,合并滤液。滤液用截留分子量为50000的聚砜膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.35Mpa,超滤的出液口压力比进液口压力低0.20kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为3.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为40℃,当料液原液被浓缩1/8时,再加水或稀醇溶液超滤2次,料液的PH值控制在7.5。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min。化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Take the coarsely crushed Rhizoma Chuanxiong and Panax notoginseng into the extraction tank, add 0.89g sodium bicarbonate, add 4 times the amount of water, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, decoct After 1 hour, filter, discard the filter residue, and combine the filtrates. The filtrate was ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 50,000, and the filtration method was cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.35Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.20kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 3.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating or unstable flows in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 40°C. When the original feed liquid is concentrated by 1/8, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 7.5. The backwash pressure is 2.5MPa, the backwash cycle is 1.5h, and the backwash time is 10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 20 minutes, recoil for 3 minutes. The chemical cleaning cycle is 2 months, the chemical cleaning agent is a mixed solution of 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10 to 12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.
将所述的超滤液浓缩得到相对密度为1.32~1.40(55℃)的浸膏,取浸膏和冰片,与聚乙二醇-6000 18g混和均匀,加热至温度85℃,化料20~120分钟后,移至罐温保持在85~90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrate the ultrafiltrate to obtain an extract with a relative density of 1.32 to 1.40 (55° C.), take the extract and borneol, mix it with polyethylene glycol-6000 18 g, heat to a temperature of 85° C. After 120 minutes, move to the dropping tank of the dropping pill machine whose tank temperature is kept at 85-90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410072940 CN1778323B (en) | 2004-11-26 | 2004-11-26 | A drug drop pill for treating cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410072940 CN1778323B (en) | 2004-11-26 | 2004-11-26 | A drug drop pill for treating cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1778323A CN1778323A (en) | 2006-05-31 |
| CN1778323B true CN1778323B (en) | 2010-05-12 |
Family
ID=36768860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410072940 Expired - Lifetime CN1778323B (en) | 2004-11-26 | 2004-11-26 | A drug drop pill for treating cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1778323B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085070B (en) * | 2006-06-08 | 2011-09-21 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing notoginseng and haw and its preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348815A (en) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use |
| CN1421241A (en) * | 2002-12-23 | 2003-06-04 | 北京采瑞医药有限公司 | Compound red sage drip pill for treating cardiac and cerebral vascular diseases and its prepn process |
| CN1422664A (en) * | 2002-12-23 | 2003-06-11 | 北京采瑞医药有限公司 | Compound preparation of root of red-rooted salvia for treating cerebrovascular and cardiovascular diseases and preparation method thereof |
-
2004
- 2004-11-26 CN CN 200410072940 patent/CN1778323B/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348815A (en) * | 2001-11-09 | 2002-05-15 | 天津天士力制药股份有限公司 | Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use |
| CN1421241A (en) * | 2002-12-23 | 2003-06-04 | 北京采瑞医药有限公司 | Compound red sage drip pill for treating cardiac and cerebral vascular diseases and its prepn process |
| CN1422664A (en) * | 2002-12-23 | 2003-06-11 | 北京采瑞医药有限公司 | Compound preparation of root of red-rooted salvia for treating cerebrovascular and cardiovascular diseases and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 冉军.试论活血化瘀法的临床应用.厂矿医药卫生14 3.1998,14(3),188-189. |
| 冉军.试论活血化瘀法的临床应用.厂矿医药卫生14 3.1998,14(3),188-189. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1778323A (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494879B (en) | A kind of ceramic membrane prepares the technique of Salvia Miltiorrhiza Oral Liquid | |
| CN1778323B (en) | A drug drop pill for treating cardiovascular disease | |
| CN1778340B (en) | Chinese medicine composition for treating coronary heart disease and angina cordis | |
| CN1778336B (en) | A kind of preparation method of compound danshen dripping pill | |
| CN1778343B (en) | A drug drop pill for treating coronary heart disease | |
| CN1778334B (en) | Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease | |
| CN1785250B (en) | A kind of traditional Chinese medicine powder injection containing salvia miltiorrhiza | |
| CN1778335B (en) | Chinese medicine for treating coronary heart disease and angina cordis | |
| CN1778337B (en) | A kind of preparation method of compound salvia miltiorrhiza tablet | |
| CN1778333B (en) | Traditional Chinese Medicine for Treating Angina Pectoris of Coronary Heart Disease | |
| CN1778339B (en) | Drug drop pills for treating angina pectoris of coronary heart disease | |
| CN1778345B (en) | Chinese Medicine Dropping Pills for Treating Coronary Heart Disease | |
| CN1778341B (en) | A drug drop pill for treating angina pectoris of coronary heart disease | |
| CN1778354B (en) | Chinese medicine dropping ball for coronary heart disease and angina cordis | |
| CN1778353B (en) | A kind of traditional Chinese medicine dripping pill for treating cardiovascular disease | |
| CN1778338B (en) | Chinese medicine composition for treating coronary heart disease and angina cordis | |
| CN1785251B (en) | A kind of medicinal powder injection containing salvia miltiorrhiza | |
| CN1778327B (en) | Drug dripping pills for the treatment of cardiovascular diseases | |
| CN101084996B (en) | Traditional Chinese medicine containing red sage root and its preparation | |
| CN1778322B (en) | A drug for the treatment of cardiovascular disease | |
| CN1751704B (en) | Traditional Chinese medicine injection containing red-rooted salvia | |
| CN1778344B (en) | drugs for coronary heart disease | |
| CN1778352B (en) | Chinese medicine composition for treating cardiovascular disease | |
| CN1778347B (en) | A kind of traditional Chinese medicine dripping pill for treating coronary heart disease | |
| CN1778342B (en) | Chinese medicine composition for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CX01 | Expiry of patent term |
Granted publication date: 20100512 |
|
| CX01 | Expiry of patent term |